The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Smulevich A.B.

Sechenov First Moscow State Medical University of Ministry of health of the Russia, Moscow, Russia

Romanov D.V.

FGBU "Nauchnyĭ tsentr psikhicheskogo zdorov'ia" RAMN, Moskva;
NOKTs "Psikhosomaticheskaia meditsina" Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Voronova E.I.

Sechenov First Moscow State Medical University, Moscow

Mukhorina A.K.

Mental Health Research Center, Moscow, Russia

Chitlova V.V.

Tsentr psikhicheskogo zdorov'ia RAMN, Moskva

Sorokina O.Yu.

Mental Health Research Center, Moscow, Russia

Evolution of the schizophrenic deficit concept

Authors:

Smulevich A.B., Romanov D.V., Voronova E.I., Mukhorina A.K., Chitlova V.V., Sorokina O.Yu.

More about the authors

Read: 5991 times


To cite this article:

Smulevich AB, Romanov DV, Voronova EI, Mukhorina AK, Chitlova VV, Sorokina OYu. Evolution of the schizophrenic deficit concept. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9):4‑14. (In Russ.)
https://doi.org/10.17116/jnevro2017117914-14

Recommended articles:
PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Schi­zophrenic spectrum diso­rders and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):136-141
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Psychosomatic sets of symptoms in schi­zotypal personality diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):46-54
Factors supporting chro­nic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15

References:

  1. Andreasen NC, Carpenter Jr WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
  2. van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M, Arango C, Fleischhacker W, Lachaux B, Kane JM. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand. 2006;113(2):91-95.
  3. Liberman YuI. Materialy kliniko-statisticheskogo izucheniya populyatsii bol’nykh shizofreniei (demograficheskie dannye i kharakter techeniya bolezni): Dis... d-ra med. nauk. M. 1971. (In Russ.).
  4. Rukovodstvo po psikhiatrii. Pod red. Snezhnevskogo A.V. M.: Meditsina; 1983. (In Russ.).
  5. Chang W, Hui CL, Tang JY, Wong GH, Lam MM, Chan SK, Chen EY. Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophrenia Research. 2011;133(1):22-28. https://doi.org/10.1016/j.schres.2011.09.006
  6. Üçok A, Ergül C. Persistent negative symptoms after first episode schizophrenia: A 2-year follow-up study. Schizophr Res. 2014;158(1-3):241-246. https://doi.org/10.1016/j.schres.2014.07.021
  7. Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS, Eufest Study G. Persistent negative symptoms in first episode patients with schizophrenia: results from the European first episode schizophrenia trial. Eur Neuropsychopharmacol. 2013;23(3):196--204. https://doi.org/10.1016/j.euroneuro.2012.04.019
  8. Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R. Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study. BMC Psychiatry. 2014;14(1):230-244. https://doi.org/10.1186/s12888-014-0225-8
  9. Mucci A. The evolution of negative symptom constructs. Paper presented at: Congress of the European Psychiatric Association 2017;1-4: Florence, Italy. http://epa-congress.org/2018/programme-submission/2017-abstract-book#.WRKFTlIqj_Q
  10. Mucci A, Merlotti E, Üçok A, Aleman A, Galderisi S. Primary and persistent negative symptoms: concepts, assessments and neurobiological bases. Schizophr Res. 2016. https://doi.org/10.1016/j.schres.2016.05.014
  11. Vnukov VA. O defekte pri shizofrenicheskom protsesse. Tr. 2-go Vsesoyuznogo s»ezda psikhiatrov i nevropatologov. M. 1937;466-470. (In Russ.).
  12. Melekhov DE. Klinicheskie osnovy prognoza trudosposobnosti pri shizofrenii. M. 1963. (In Russ.).
  13. Smulevich AB, Vorob’ev VYu. Psikhopatologiya shizofrenicheskogo defekta. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova. 1988;88:100-105. (In Russ.).
  14. Barkhatova AN. Defitsitarnye rasstroistva na nachalnykh etapakh yunosheskogo endogennogo pristupoobraznogo psikhoza (multidistsiplinarnoe issledovanie): Dis... d-ra med. nauk. M. 2016. Avaliable at: http://www.dissercat.com/content/endogennyi-yunosheskii-pristupoobraznyi-psikhoz-s-katatonicheskimi-rasstroistvami-v-struktur (In Russ.).
  15. Janzarik W. Dynamische Grundkonstellationen in endogenen Psychosen. Berlin—Göttingen—Heidelberg: Springer; 1959.
  16. Tandon R, DeQuardo JR, Taylor SF, et al. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophrenia Research. 2000;51:185-201.
  17. Lincoln TM, et al. Current developments and challenges in the assessment of negative symptoms. Schizophrenia Research. 2016. https://doi.org/10.1016/j.schres.2016.02.035
  18. Smulevich AB, Romanov DV, Mukhorina AK, Atadzhikova JA. «Verschrobene»-phenomenon in schizophrenia and schizophrenia spectrum disorders: aspects of systematics. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(1):5-16. (In Russ.). https://doi.org/10.17116/jnevro2017117115-16
  19. Smulevich AB. Schizophrenia spectrum disorders in general medical practice. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2016;116(1):4-9. (In Russ.). https://doi.org/10.17116/jnevro2016116114-9
  20. Stone WS, Hsi X, Giuliano AJ, et al. Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically? Results from the Changsha study. Asian J Psychiatr. 2012;5:1:73-82. https://doi.org/10.1016/j.ajp.2011.12.001
  21. Barkhatova AN. Kliniko-psikhopatologicheskie aspekty defitsitarnykh rasstroistv v strukture nachal’nykh etapov yunosheskogo endogennogo psikhoza. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115;9:8-16. (In Russ.). https://doi.org/10.17116/jnevro2015115918-16
  22. Rabello A. Clinical Psychopathology of Negative Symptoms, A phenomenological Perspective. Paper presented at: Congress of the European Psychiatric Association 2017;1-4:Florence, Italy. http://epa-congress.org/2018/programme-submission/2017-abstract-book#.WRKFTlIqj_Q
  23. Jorgensen A, Parnas J. The Copenhagen High-Risk Study. Premorbid and clinical dimensions of maternal schizophrenia. J Nerv Ment Dis. 1990; 178:6:370-376.
  24. Dominguez MdG, Saka MC, Lieb R, Wittchen H-U, Os van J. Early expression of negative/disorganized symptoms predicting psychotic experiences and subsequent clinical psychosis: a 10-year study. American Journal of Psychiatry. 2010;167:1075-1082.
  25. Janssens M, Boyette LL, Heering HD, Bartels-Velthuis AA, Lataster T. Developmental course of subclinical positive and negative psychotic symptoms and their associations with genetic risk status and impairment. Schizophr Res. 2016;174:1-3:177-82. https://doi.org/10.1016/j.schres.2016.03.028
  26. Kraepelin E. Die Verschrobenen. In: Psychiatrie. Leipzig; 1915:2039-2043.
  27. Birnbaum K. Über degenerativ Verschrobene. Zbl Nervenheilk. 1906.
  28. Panteleeva GP. O vyalotekushchei shizofrenii s klinicheskimi izmeneniyami psikhastenicheskogo tipa. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova. 1965;65:11:1690-1698. (In Russ.).
  29. Pinel P, Davis D. A treatise on insanity, in which are contained the principles of a new and more practical nosology of maniacal disorders than has yet been offered to the public ... 1st ed. Washington, D.C.: University Publications of America; 1977.
  30. Haslam J. Observations on Madness and Melancholy: Including practical Remarks on those Diseases; together with Cases: and an Account of the morbid Appearances on Dissection. 1st ed. London; 1809.
  31. Butkovskii PA. Dushevnye bolezni, izlozhennye soobrazno nachalam nyneshnego ucheniya psikhiatrii v obshchem i chastnom, teoreticheskom i prakticheskom soderzhanii. SPb. 1834. (In Russ.).
  32. Malinovskii PP. Pomeshatelstvo, opisannoe tak, kak ono yavlyaetsya vrachu v praktike. SPb. 1847. (In Russ.).
  33. Morel B. Traité des maladies mentales. 1st ed. Paris: Masson; 1860.
  34. Jackson J. On Post-Epileptic States: A Contribution to the Comparative Study of Insanities. The British Journal of Psychiatry. 1889;34(148):490-500.
  35. Shizofreniya: Mul’tidistsiplinarnoe issledovanie. Pod red. Snezhnevskogo A.V. M.: Meditsina; 1972. (In Russ.).
  36. Strauss J, Carpenter W, Bartko J. Part III. Speculations on the Processes That Underlie Schizophrenic Symptoms and Signs. Schizophrenia Bulletin. 1974;1:11:61-69.
  37. Andreasen N. Negative Symptoms in Schizophrenia. Archives of General Psychiatry. 1982;39(7):784.
  38. Carpenter W, Heinrichs D, Wagman A. Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry. 1988;145(5): 578-583.
  39. Berrios G. Positive and Negative Symptoms and Jackson. Archives of General Psychiatry. 1985;42(1):95.
  40. Monro H. Remarks on insanity. 1st ed. London: Churchill; 1851.
  41. Chambers T. The Renewal of Life: clinical lectures illustrative of the restorative system of medicine, given at Saint Mary’s Hospital. 1st ed. London: John Churchill; 1863.
  42. Anstie F. Stimulants and narcotics, their mutual relations. 1st ed. New York: Arno Press; 1981.
  43. Tuke DH. Imperative ideas. Brain. 1894;17:177-197.
  44. Rutherford WM: Lectures on experimental physiology: Lecture IV: Innervation. Lancet. 1871;1:563-567.
  45. Reynolds J. Epilepsie; ihre Symptome, Behandlung und ihre Beziehungen zu andern chronisch-convulsiven Krankheiten. 1st ed. Erlangen: Enke; 1865.
  46. Jackson J. On temporary mental disorders after epileptic paroxysms. West Riding Lunatic Asylum Med Rep. 1875;5:105-129.
  47. Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh: Livingstone; 1919.
  48. Bleuler E. Dementia Praecox oder Gruppe der Schizophrenien. Leipzig: Deuticke; 1911.
  49. Griesinger W. Vortrag zur Eroeffnung der psychiatrischen Klinik zu Berlin. Archiv fuer Psychiatrie und Nervenheilkunde. 1868;1(1):143-158.
  50. Kirkpatrick B. The Heterogenety of schizophrenia: Implications for research on Biomarcers. Paper presented in: Abstract Book of 15th World Congress of Psychiatry. Buenos Aires. 2011.
  51. Ey H. Études psychiatriques. Descleé de Brouwer: Paris; 1952.
  52. Rukovodstvo po psikhiatrii v dvukh tomakh. Pod red. Snezhnevskogo A.V. M.: Meditsina; 1983. (In Russ.).
  53. Favorina V.N. O konechnykh sostoyaniyakh gebefrenicheskoi formy shizofrenii. Zhurnal nevropatologii i psikhiatrii im S.S. Korsakova. 1964;64:4:592. (In Russ.).
  54. Langfeldt G. The schizophreniform states. A katamnestic study based on individual reexaminations. With special reference to diagnostic and prognostic clues, and with a view to presenting a standard material for comparison with the remissions effected by schock treatment. Copenhagen, Munskgaard, London: Milford; 1939.
  55. Schneider K. Primare und secundare Symptome bei Schizophrenie. Fortschritte der Neurologie, Psychiatrie und ihre Grenzgebiete. 1957;25:487-498.
  56. Carpenter WT. One Hundred Years. Schizophr Bull. 2011;37:3:443-444. https://doi.org/10.1093/schbul/sbr032
  57. Dollfus S, Lyne J. Negative symptoms: history of the concept and their position in diagnosis of schizophrenia. Schizophr Res. 2016;8. https://doi.org/10.1016/j.schres.2016.06.024
  58. Andreasen N, Olsen S. Negative vs positive sсhizophrenia. Definition and validation. Arch Gen Psychiatry. 1982;39:789-794.
  59. Crow TJ. Positive and Negative Schizophrenic Symptoms and the Role of Dopamine. Br J Psychiatr. 1980;151:199-204.
  60. Trimble M.R. Positive and negative symptoms in psychiatry. Br J Psychiatry. 1986;148:587-589.
  61. Sass H. The historical evolution of the concept of negative symptoms in schizophrenia. Br J Psychiatry Suppl. 1989;7:26-31; discussion 37-40.
  62. Mosolov SN. Shkaly psikhometricheskoi otsenki simptomatiki shizofrenii i kontseptsiya pozitivnykh i negativnykh rasstroistv. M. 2001. (In Russ.).
  63. Huber G. Das Konzept substratnaher Basissymptome und seine Bedeutung fur Theorie und Therapie schizophrener Erkrankungen. Nervenarzt. 1983;54:23-32.
  64. Buchanan R. W. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33:1013-1022. https://doi.org/10.1093/schbul/sbl057
  65. Messinger JW, Trémeau F, Antonius D, Mendelsohn E, Prudent V, Stanford AD, Malaspina D. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev. 2011;31(1):161-168. https://doi.org/10.1016/j.cpr.2010.09.002
  66. Gruber O. Von der Psychopathophysiologie zur Biomarker-basierten Klassifikation und stratifizierten Therapie schizophrener Störungen. Fortschr Neurol Psychiatr. 2014;82:439-446.
  67. Barnes TR, Leeson VC, Mutsatsa SH, Watt HC, Hutton SB, Joyce EM. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry. 2008;193:3:203-209.
  68. Edel’shtein AO. Iskhodnye sostoyaniya shizofrenii. M.: Izdanie 1-go MMI; 1938. (In Russ.).
  69. Leonhard K. Aufteilung der endogenen Psychosen. 5 Aufl. Berlin; 1980.
  70. Mayer-Gross W. Über die Stellungnehme zur abgelaufenen akuten Psychose. Eine Studie über verständliche Zugammenhänge in der Schizophrenie. Zeitschrift fur die gesamte Neurologie und Psychiatrie. 1920;60:160-213.
  71. Vie J. Quelques terminaisons des delires chroniques. Ann Med Psychol. 1939;2:97-103.
  72. Yastrebov VS. Dlitelnye vnutribolnichnye remissii pri shizofrenii (voprosy kliniki i sotsialno-trudovoi adaptatsii): Dis... kand. med. nauk. M. 1977. (In Russ.).
  73. Il’ina NA, Zakharova NV. Dinamika pristupoobraznoi shizofrenii s dlitel’nymi remissiyami. Psikhiatriya. 2010;1(43):26-36. (In Russ.).
  74. Romanov DV, Mukhorina AK. Defekt tipa «fershroben» pri shizofrenii i zabolevaniyakh shizofrenicheskogo spektra. XIII Vserossiiskaya Shkola molodykh psikhiatrov «Suzdal’-2017»; Aprel’ 23—28, 2017; Suzdal’. (In Russ.).
  75. Huber G. Coenestetische schizophrenie. Fortshr Neurol Psychiatr. 1957; 25(9):491-520.
  76. Zhang T, Good Mary-Jo D, Good BJ, et al. Age and remission of personality pathology in the psychotic disorders compared to mood and/or anxiety disorders. Int J Psychiatry Med. 2012;44(3):241-255.
  77. Gross G. The «basic» simptoms of schizophrenia. Br J Psychiat. 1989;155(7): 21-25.
  78. Akiskal HS. Dythymic disorder: Psychopathology of proposed chronic depressive subtypes. Am J Psychiat. 1983;14:11-20.
  79. Chitlova VV, Sorokina OYu. Fazno-protekayushchie negativnye rasstroistva i affektivnaya patologiya (na modeli nevroticheskoi depressii). XIII Vserossiiskaya Shkola molodykh psikhiatrov «Suzdal’-2017»; Aprel’ 23—28, 2017; Suzdal’. (In Russ.).
  80. Morozov VM. K klinike i psikhopatologii depressivnykh sostoyanii v initsial’noi stadii shizofrenii. Trudy nauchnoi konferentsii «Voprosy sotsial’noi i klinicheskoi psikhiatrii»; mai 23—24, 1968. M. (In Russ.).
  81. Yong-Ku Kim, Joonho Choi, Seon-Cheol Park. A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia. Int J Mol Sci. 2017; 18:734. https://doi.org/10.3390/ijms18040734
  82. Leucht S, Corves C, Arbter D et al. Second-generation versus ferst-generation antipsychotic drugs for schizophrenia; a meta-analysis. Lancet. 2009;373:31-41.
  83. Nemeth G, Laszlovszky, Czobor P et al. Cariprazine vrsus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomsed double-blind, controlled trial. Lancet. 2017;389:1103-1113.
  84. Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103-1113. https://doi.org/10.1016/S0140-6736(17)30060-0
  85. Lincoln TM, Dollfus S, Lyne J. Current developments and challenges in the assessment of negative symptoms. Schizophrenia Research. 2016. https://doi.org/10.1016/j.schres.2016.02.035
  86. Cornblatt BA. The New York high risk project to the Hillside recognition and prevention (RAP) program. Am J Med Genet. 2002;114(8):956-66. https://doi.org/10.1002/ajmg.b.10520
  87. Schimmelmann BG, Huber CG, Lambert M, Cotton S, McGorry PD, Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res. 2008;42(12):982-990.
  88. Marshall M, Husain N, Bork N et al. Impact of early intervention services on duration of untreated psychosis: data from the National EDEN prospective cohort study. Schizophr Res. 2014;159(1):1-6.
  89. Carpiniello B. Importance of First Episodes and DUI/DUP. Paper presented at: Congress of the European Psychiatric Association 2017; April 1—4. Florence, Italy. 2017. http://epa-congress.org/2018/programme-submission/2017-abstract-book#.WRKFTlIqj_Q
  90. Murru A, Carpiniello B. Duration of untreated illness as a key to early intervention in schizophrenia: A review. Neurosci Lett. 2016;4. https://doi.org/10.1016/j.neulet.2016.10.003
  91. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785-1804.
  92. Azorin JM, Belzeaux R, Adida M. Negative symptoms in schizophrenia: where we have been and where we are heading. CNS Neuroscience and Therapeutics. 2014;20:801-808. https://doi.org/10.1111/cns.12292
  93. Minkowski E. La schizophrénie. Psychopathologie des schizoïdes et des schizophrènes. Paris: Payot; 1927.
  94. Khar’kova GS. Asteniya v strukture negativnykh rasstroistv shizofrenii. Psikhiatriya. 2016;71(3):84-85. (In Russ.).
  95. Dubnitskaya EB. Maloprogredientnaya shizofreniya s preobladaniem istericheskikh rasstroistv (klinika, differentsial’naya diagnostika, terapiya): Dis... kand. med. nauk. M. 1979. (In Russ.).
  96. Zhilin VO. K kharakteristike defekta pri shizofrenii s istericheskimi rasstroistvami. Psikhiatriya. 2017. (In Russ.).
  97. Il’ina NA. Shizofrenicheskie reaktsii (aspekty tipologii, prediktsii, kliniki, terapii): Dis... d-ra med. nauk. M. 2006. Ssylka aktivna na 04.05.17. Dostupno po: http://www.psychiatry.ru/cond/0/diss/2006/11 (In Russ.).
  98. Иконников Д.В. Реакции отказа при вялотекущей шизофрении: Дис... канд. мед. наук. М. 2005. http://ncpz.ru/cond/0/diss/2005/14 [Ikonnikov DV. Reaktsii otkaza pri vyalotekushchei shizofrenii: Dis... kand. med. nauk. M. 2005. Dostupno po: http://ncpz.ru/cond/0/diss/2005/14
  99. Samushiya MA. Psikhicheskie rasstroistva u bolnykh zlokachestvennymi novoobrazovaniyami organov zhenskoi reproduktivnoi sistemy (klinika, epidemiologiya, terapiya): Dis... d-ra med. nauk. M. 2015. Avaliable at: http://ncpz.ru/cond/0/diss/2015/231 (In Russ.).
  100. Ivanov SV, Petelin DS. Tipologiya nozogennykh reaktsii s yavleniyami autoagressii (fenomen otkladyvaniya) pri zlokachestvennykh novoobrazovaniyakh. Psikhicheskie rasstroistva v obshchei meditsine. 2016;3:17-25. (In Russ.).
  101. Oleichik IV. Yunosheskie depressii s «yuvenilnoi astenicheskoi nesostoyatelnostyu» (psikhopatologiya, diagnostika, prognoz): Dis... kand. med. nauk. M.; 1997. Ssylka aktivna na 04.05.17. Dostupno po: http://ncpz.ru/cond/0/diss/2011/178 (In Russ.).

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.